国产99热精品_欧美疯狂做受xxxx猛交_婷婷在线网站_日韩无遮挡毛片_欧美高清momspuss_欧美激情福利

再鼎醫(yī)藥是一家致力于研究、開(kāi)發(fā)和銷售創(chuàng)新藥物的制藥企業(yè)。再鼎醫(yī)藥針對(duì)目前尚無(wú)良好治療手段的疾病領(lǐng)域開(kāi)發(fā)新藥，以改善全球病人的生活質(zhì)量。再鼎醫(yī)藥通過(guò)內(nèi)部研發(fā)和授權(quán)許可等方式建立全面的產(chǎn)品線。我們希望公司開(kāi)發(fā)的新藥能夠遏制疾病，并為患者帶來(lái)顯著療效。

再鼎醫(yī)藥創(chuàng)建于2013年，公司擁有一支在全球制藥企業(yè)和研發(fā)機(jī)構(gòu)富有經(jīng)驗(yàn)的世界級(jí)管理團(tuán)隊(duì)。這支擁有卓越成功經(jīng)驗(yàn)的創(chuàng)始人團(tuán)隊(duì)被譽(yù)為中國(guó)快速發(fā)展的生物技術(shù)產(chǎn)業(yè)的先驅(qū)，曾帶領(lǐng)多個(gè)成品成功獲得中國(guó)和美國(guó)食品藥品監(jiān)督管理局的認(rèn)可。這支團(tuán)隊(duì)最先在中國(guó)嘗試新藥快速審批途徑并獲得批準(zhǔn)，同時(shí)也與多個(gè)跨國(guó)制藥巨頭建立了長(zhǎng)期的戰(zhàn)略合作伙伴關(guān)系。在再鼎醫(yī)藥，團(tuán)隊(duì)將繼續(xù)投身于在中國(guó)為世界開(kāi)發(fā)高質(zhì)量的創(chuàng)新藥。

再鼎醫(yī)藥獲得數(shù)家生物醫(yī)藥領(lǐng)域的全球頂級(jí)投資機(jī)構(gòu)的支持，包括啟明創(chuàng)投基金，凱鵬華盈中國(guó)基金，紅杉資本和泰福資本。這些投資機(jī)構(gòu)都將堅(jiān)定地支持再鼎醫(yī)藥成長(zhǎng)為生物醫(yī)藥領(lǐng)域的國(guó)際領(lǐng)先企業(yè)。

Zai Lab is a biopharmaceutical company dedicated to discovering, developing and commercializing innovative medicines. Our vision is to address the largest unmet medical needs and transform patients’ lives around the world. We take a unique approach to combine both in-licensed products and internal R&D to achieve a rich pipeline. We believe our drug candidates can be truly disease modifying and bring significant benefits to patients.

The company was founded in 2013 by a group of industry veterans. The founders are known as pioneers in China’s fast advancing biotech industry with a proven track record for successful Chinese CFDA and US FDA filings and approvals. Our senior management team introduced fast regulatory approval pathways in China and developed a variety of partnership models with multinational pharmaceutical companies. We endeavor to conduct world class clinical development in China and beyond.

Zai Lab has strong backing from a leading group of healthcare investors including Qiming Venture Partners, Kleiner Perkins Caufield & Byers, Sequoia Capital and TF Capital. Our investors are committed to support Zai Lab to become a global biopharmaceutical leader based in China.